PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, making it one of the most valuable biotech companies in the country. With this funding, PlasmaGen has now raised over ₹600 crore to date, demonstrating the confidence of investors in its mission to revolutionize the plasma fractionation industry.
PlasmaGen Biosciences is a leading player in the plasma fractionation industry, operating one of India’s five plasma fractionation facilities near Bengaluru. The company’s state-of-the-art facility is equipped with cutting-edge technology, enabling it to produce high-quality plasma-derived products that cater to the growing demand for these life-saving therapies. With a strong focus on research and development, PlasmaGen is committed to developing innovative products that address the unmet medical needs of patients in India and globally.
The funding round was led by ViNS Bioproducts, a renowned biotech company with a strong track record of investing in innovative biotech startups. Other notable investors, including Eight Roads, FIL Capital, and F-Prime, also participated in the round, demonstrating their confidence in PlasmaGen’s vision and growth potential. The investment will be utilized to expand PlasmaGen’s manufacturing capacity, enhance its research and development capabilities, and strengthen its market presence in India and internationally.
The plasma fractionation industry has witnessed significant growth in recent years, driven by the increasing demand for plasma-derived products. These products are used to treat a range of life-threatening diseases, including hemophilia, immunodeficiency disorders, and infectious diseases. With a large and growing patient population, India offers a vast market opportunity for companies like PlasmaGen to make a meaningful impact. By leveraging its expertise and capabilities, PlasmaGen is well-positioned to capitalize on this trend and emerge as a leader in the global plasma fractionation industry.
The funding raise is a testament to the company’s strong fundamentals and growth prospects. PlasmaGen’s commitment to quality, innovation, and patient-centricity has earned it a reputation as a trusted partner in the biotech industry. With a seasoned management team and a strong team of scientists and researchers, the company is poised to achieve its vision of becoming a global leader in plasma fractionation.
The Indian biotech industry has witnessed significant growth in recent years, with several companies raising substantial funding to drive innovation and expansion. The government’s initiatives to promote the biotech sector, including the establishment of biotech parks and funding schemes, have also contributed to the sector’s growth. With a large and growing market, a skilled workforce, and a favorable business environment, India is emerging as a hub for biotech innovation, and companies like PlasmaGen are at the forefront of this revolution.
In conclusion, PlasmaGen’s ₹150 crore funding raise is a significant milestone for the company and the Indian biotech industry. With a valuation of over ₹1,500 crore, PlasmaGen has demonstrated its potential to become a global leader in the plasma fractionation industry. As the company continues to expand its capabilities and market presence, it is likely to make a meaningful impact on the lives of patients in India and globally. With its strong fundamentals, innovative products, and commitment to quality, PlasmaGen is poised to achieve its vision of becoming a leading player in the global biotech industry.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
